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Summary  The present study was examined that modulators of semicarbazide-sensitive amine 
oxidase (SSAO; EC 1.4.3.6.) might be present in the brain cytosol and looked for changes in SSAO 
modulatory activity in brain cytosol. An endogenous inhibitor of SSAO (ESI) was separated by gel 
filtration from 105,000 g supernate of thyroxine (T4)-treated rat brain cytosol. The inhibition by this 
inhibitor with SSAO activity for 1 µmol/L benzylamine was concentration dependent. The mode of 
inhibition was competitive with benzylamine. The molecular weight of this inhibitor was estimated 
to be 600-700 by gel filtration. The pI value of ESI was determined by isoelectric focusing (IEF)-gel 
electrophoresis to about 3.6. SSAO inhibition activity was much lower in the cytosol of 
thyroidectomized, non-T4-treated rats than T4-treated rats, suggesting that this inhibitor is induced 
by thyroid hormone. SSAO activity in rat brain might be regulated by the level of this inhibitor. The 
results indicate that this inhibitor in T4-treated rat brain cytosol and that the level of this inhibitor 
is regulated by thyroid hormone. 
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Introduction 
Several different amine oxidases are inhibited by carbonyl 
reagents, such as semicarbazide. The  semicarbazide - 
sensitive amine oxidase (SSAO; EC 1.4.3.6.)1),2) are 
resistant to inhibition by acetylenic inhibitors, such as 
clorgyline, deprenyl, and pargyline3). SSAO differs from 
monoamine oxidase (MAO; EC 1.4.3.4) and deaminates 
various monoamines4),5). SSAO activity is suspected to 
cause damage, such as diabetes in humans6),7). Despite of 
widespread tissue distribution this enzyme8),9), is 
physiological role remain far from clear10). This enzyme is 
highly sensitive to carbonyl reagents. One of the important 
actions of thyroid hormone is thought to be the regulation 
of protein synthesis and enzyme activities11),12). Therefore, I 
hypothesized that modulators of SSAO might be present in 
the brain cytosol and looked for changes in SSAO 
modulatory activity in brain cytosol of thyroidectomized 
rats during thyroid hormone treatment. It is not clear 
whether thyroid hormones affect the synthesis of SSAO or 
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act by another mechanism (e.g. Induction of specific 
modulator). Our results indicate that certain modulators 
are induced by thyroid hormone administration and that 
these modulators inhibit SSAO activity by a competitive 
mechanism. 
Materials and methods 
Materials 
Benzylamine hydrochloride, Thyroxine (T4) sodium salt, 
subtilisin protease Type III), protease E (protease Type 
XIV) and trypsin were purchased from the Sigma 
Chemical Co. (St. Louis, MO, USA). The radioactive 
substrate [7-14C]-benzylamine hydrochloride (1.85-2.29 
Gbq/mmol) was obtained from Amersham International 
(Amersham, England). Servalyte (pH 2-11) was purchased 
from Serva Fine Biochemical Co. (St. Louis, MO, USA). 
 
Isolation of SSAO Inhibitor 
Thyroidectomized rats (Male Wistar), weighing 100-150 
g, were used for experiments. In the case of T4 
administered rats, T4 (dissolved in saline) was injected 
subcutaneously to the rats 10 days after from operation at 
a dose of 200 µg/kg per day for 2 weeks. T4 sodium salt 
were purchased from the Sigma Chemical Co. (St. Louis, 
MO, USA). The rats were killed by decapitation and brain 
quickly removed and homogenized in 10 vol. of 10 mmol/L 
phosphate buffer, pH 7.4 containing 0.32 mol/L sucrose. 
The homogenates (10 mg protein) was centrifuged at 
105,000 g for 60 min, and the supernate (cytosol fraction) 
was applied on a Sephadex G-25 column (1.0×60 cm), 
previously equilibrated with 20 mol/L phosphate buffer 
(pH 7.4). The column was eluted with the same buffer at a 
rate of 10 ml/hr and the fractions were collected in 2.5 ml 
each. An aliquot of each fraction was assayed for SSAO 
inhibition activity, and active fractions were combined and 
used for further characterization. This fraction is referred 
to as "endogenous SSAO inhibitor (ESI)". All procedures in 
dealing with the experimental animals met the guideline 
principles stipulated by the Physiological Society of Japan 
and the Animal Ethics Committee of the Oita Medical 
University, Japan. 
 
Assay of SSAO activity 
Rat brain homogenate fraction was used as a source of 
SSAO activity. The 10% homogenate was prepared in 0.32 
M sucrose with 10 mmol/L phosphate buffer, pH 7.4. SSAO 
activity was assayed radiochemically as described by 
Bitsios et al.13). Assay mixture contained 20 µL of 
homogenate fraction (1 mg/ml protein), [14C]-benzylamine 
(1 µmol/L), in 20 mmol/L phosphate buffer, pH 7.4 in the 
presence of ESI (0-150 µL). Protein concentrations of the 
preparations were measured by the method of Lowry et 
al.14)  with bovine serum albumin as the standard. 
 
Isoelectric focusing (IEF) 
Gel isoelectric focusing (IEF) was performed15). The final 
composition of the gel was 5% acrylamide, 0.2% methylene 
bisacrylamide, 0.75 % Triton X 100, 2% servalyte (pH 2-11), 
0.0002% riboflavin, 0.01% ammonium persulfate, 0.05% 
TEMED (N,N,N'N'-tetramethylenediamine). The gel was 
mounted on a vertical apparatus containing 0.01 mol/L 
H3PO4 in the upper tank (anode) and 0.02 mol/L NaOH in 
the lower tank (cathode). The current was at 100 V for the 
first 1 hr, 200 V for the next 2 hr and then 300 V for 2 hr. 
After electrophoresis, the gel was cut into 4 mm thick slices 
and each sliced gel was placed in a test tube, and incubated 
for 1 hr at room temperature by adding 1 mL of distilled 
water and bubbled with N2 gas. After the measurement of 
slice pH, a minimum amount of 0.5 mol/L H3PO4 was 
added to adjust the pH to 7.4. An aliquot of each slice 
suspension was then assayed for SSAO inhibition activity 
with benzylamine as a substrate. 
 
Heat treatment and digestion with pepsin and trypsin 
For determination of heat stability of ESI was heat at 
100 ˚C for 10 min. The samples were then added to 
homogenate preparations to determine their effects on 
SSAO activity. Also ESI were treated with subtilisin or 




All values are presented as means±S.E.M. The 
significance of difference was determined by using ANOVA 
with Fisher's post hoc test. A P value of less than 0.05 was 
regarded as being statistically significant. 
Results 
The gel-filtration of T4-treated rat brain cytosol with 
Sephacryl S-200 column showed that the fractions to 
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inhibit SSAO activity were eluted in a low molecular 
weight area (<2000) (data not shown). Therefore, I used 
Sephadex G-25 column to separate the inhibitor and 
determine the molecular size (Fig.1). The fractions 19-21 
were found to inhibit SSAO activity with 1 µmol/L 
benzylamine was a substrate. The molecular weight of the 
inhibitor was estimated to be 600-700. When 
thyroidectomized, non-T4-treated rats were used 
(ESI-control), the inhibition activities for 1 µmol/L 
benzylamine were very low. T4-treatment remarkably 
enhanced SSAO inhibition activities for substrate. This 
results suggests that the inhibitor could be induced by T4 
treatment. The inhibition curves of SSAO activity by ESI 
were concentration-dependent, and IC50 values for 1 
µmol/L benzylamine oxidation was 143 µL (Fig.2). To know 
the mode of ESI inhibition, the inhibition was investigated 
with different substrate concentrations. Fig.3 shows 
Lineweaver-Burk plots of the results with benzylamine as 
substrate. ESI inhibited SSAO activity competitively. ESI 
applied at a variety of volumes (50, 100 and 150 µL) 
increased the Km values for benzylamine from 1.3 to 30.3 
µmol/L, but did not alter Vmax values. pl value of ESI was 
determined by gel isoelectric-focusing. SSAO inhibition 
activity was found as a single peak at a position 2.0 cm 
from the top of the gel. The pH measurement after 
isoelectric focusing revealed that ESI has a pI value of 
about 3.6 (Fig.4). When ESI were treated at 100 ˚C for 10 
min, the inhibition activity was not changed. Also, 
treatment of ESI with subtilisin or pronase at 37 ˚C for 12 
hr did not affect the inhibition activity of ESI. These results 
suggest that ESI is a non-peptide inhibitor. Moreover, ESI 
was inactivated with trypsin at 37 ˚C for 30 min digestion. 
Discussion 
In the present study, I have demonstrated the presence 
of ESI in rat brain cytosol fraction of thyroid hormone 
inducible modulator, which inhibit SSAO activity. To my 
knowledge, this is first report on SSAO modulator in rat 
brain. It is well established that one of the action of thyroid 
hormones is thought to be the regulation of protein 
synthesis and enzyme activities16). The fact that the 
inhibitory activity in the hyperthyroid state suggests the 
possibility that thyroid hormone may regulate the SSAO 
activity by induction of this inhibitory modulator. However, 
it is not known whether such as a decrease in SSAO 
activity in hyperthyroid state is a direct effect of thyroid 
hormone or mediated through specific mechanism. I found 
an endogenous SSAO modulator of a low molecular weight 
(600-700) in brain cytosol of T4 treated rats (Fig.1). As far 
as I known, this is the first isolation of the endogenous 
inhibitor of SSAO from the T4-treated rat brain. The 
inhibitory effects of this inhibitor was non-linear 
concentration-dependent (Fig.2). When thyroidectomized, 
non-treated rats were used (ESI control), inhibition 
activities for benzylamine were very low. T4-treatment 
remarkably enhanced SSAO inhibition activities for 
benzylamine. 
Dilution experiments showed that the dilution of the 
reaction mixture restored the activity to the level at final 
concentration of the inhibitor (data not shown), suggesting 
that the inhibition is reversible. This may indicates that 
ESI was a reversible inhibitor of SSAO. A kinetical study 
showed that ESI increased the Km values for benzylamine 
but did not alter Vmax values (Fig.3). The mode of ESI 
inhibition was competitive. The competitive kinetics were 
obtained at high benzylamine concentration (100 µmol/L) 
associated with MAO enzyme, not at the low (1 µmol/L) 
concentration of SSAO8). Therefore, when ESI increased in 
the hyperthyroid state, thyroid hormone not only SSAO, 
but also may regulate the MAO activity by induction of this 
inhibitory modulator. From these results, it can be 
concluded that the rat brain contains low molecular weight 
materials which act like SSAO inhibitor drugs. ESI may be 
a low molecular weight compound such as certain 
monoamines or their metabolites, β-carboline17) or 
tribuline18). The pI value of ESI was determined by IEF-gel 
electrophoresis to about 3.6 (Fig.4). This result indicate 
that ESI is an acidic compound. Although the nature of 
this inhibitor is not clear at present, the present study 
showed that this compound is heat-stable and resists to 
protease, subtilisin and trypsin treatment. My findings 
suggested that modulators induced by thyroid hormone 
may have an important role in SSAO activity. The 
observations that T4 did not affect SSAO activity directly 
in vitro and that treatment with T4 did not directly affect 
the level of SSAO indicate that thyroid hormone induced




Sephadex G-25 chromatography of cytosolic fraction from T4-treated rat brain. Cytosolic fraction (10 mg protein)  was 
applied  to a Sephadex G-25 column (1.0×60 cm). ESI control (closed circle) or ESI-T4 (open circle) was obtained from 
thyroidectomized rat or thyroidectomized, T4 treated rat, respectively, as described in the text. The activity of SSAO in 
homogenate was assayed with 1 µmol/L benzylamine as a substrate. Arrows indicate the position of marker compounds. 
The molecular for markers used were as follows: a, cyanocobalamine (MW, 1,355); b, FAD (MW, 786); c, DNP-Alanine (MW, 
255). Vo; dextran (MW, 2,000,000). The broken line shows the absorbance at 280 nm. 
 
Figure 2 
Concentration-dependent effect of ESI without preincubation. Inhibition of SSAO activity by ESI-control (closed circle) and 
ESI-T4-treated rat (open circle) were tested. In the presence of ESI, SSAO activity in rat brain homogenate was determined 
1 µmol/L benzylamine as substrate at 37 ˚C for 10 min. The control activity for 1 µmol/L benzylamine was 0.14±0.03 
nmol/min/mg protein. The values represent the mean percentage (±SE) of SSAO activity. Values are means±S.E.M. for six 
animals. *P<0.05 significant difference between the data connected by bracket (ANOVA and Fisher test). 
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Lineweaver-Burk plots of the reciprocal of the initial velocity of benzylamine oxidation against reciprocal of the substrate 
concentration in the presence of ESI without preincubation. Sample assayed for activity in the absence (open circle) and 
presence of 150 µL (closed circle), 100 µL (triangle) and 50 µl (square) ESI, with benzylamine as substrate. Abscissa, 
1/substrate concentration in mM (mmol/L); ordinate, 1/initial velocity in nmol/min/mg protein. Each point represents the 




Estimation of pl value of ESI-T4 in rat brain cytosol by gel isoelectric focusing. ESI-T4 fraction was collected and was 
solubilized with 0.75% Triton X-100. Isoelectric focusing was performed as described in Materials and Methods. After 
IEF-gel electrophoresis, the gel was cut into 4-mm slices, and the pH (open circle) of each gel slice was determined. After 
adjusting pH to 7.4, the SSAO activity for 1 µmol/L benzylamine was determined in the presence of each gel slice (closed 
circle). The control activity for benzylamine was 0.14±0.03 nmol/min/mg protein. Each point represents the mean 
percentages (±SE) on the control SSAO activity in triplicate experiments. 
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SSAO inactivation does not occur in the absence of 
modulator. 
Conclusion 
In the present study, I found a new SSAO inhibitory 
modulator in T4-treated rat brain cytosol and that the level 
of this modulator is regulated by thyroid hormone. 
Although the physiological role of this inhibitor still 
remains unclear, I consider that this modulator may play 
some role in regulating the SSAO activity in rat brain. 
While the role of these modulators is no doubt important, 
their mechanisms remain to be elucidated. 
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が存在するか否かについて調べた。遠心分離によりチロキシン（Ｔ４） 処理したラット脳の 105,000 g 分画から内因性ＳＳＡ
Ｏ阻害剤（ＥＳＩ）を分離した。この阻害剤は1 µmol/L ベンジルアミンを基質とするＳＳＡＯ活性は濃度依存的に阻害した。
阻害モードはベンジルアミンに対して競合的であった。ゲル濾過法により分子量を求めると 600-700位で、等電 （ＩＥＦ）電
気泳動法によりＥＳＩのpI値はおよそ3.6でした。ＳＳＡＯ阻害活性は甲状腺ホルモンにより誘発されるＴ４処理ラットよりＴ
４未処理の甲状腺摘出ラットは非常に小さかった。ラット脳中のＳＳＡＯ活性はこの阻害剤のレベルによって調節されているに
違いない。以上の結果はＴ４処理したラット脳細胞質中の阻害剤のレベルは甲状腺ホルモンにより調節されていることを示して
いる。 
 
キーワード：セミカルバザイド感受性アミン酸化酵素（ＳＳＡＯ）、モノアミン酸化酵素（ＭＡＯ）、甲状腺ホルモン、 
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